Market Overview

UPDATE: Morgan Stanley Downgrades Teva Pharmaceutical on Earnings Pressure

Related TEVA
Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Revenue
Teva Reports Results of Strategic Review, Sees 14 Pipeline Projects Possible for Divestment, Discontinuation
Sofinnova Ventures Closes $500M Fund (Fox Business)

In a report published Monday, Morgan Stanley analyst David Risinger downgraded Teva Pharmaceutical (NYSE: TEVA) from Equal-Weight to Underweight, and removed the $40.00 price target.

In the report, Morgan Stanley noted, “Earnings face significant pressure in 2014-2017E when Copaxone, Treanda, and Nuvigil go generic. Copaxone margin pressure offsets cost cuts in our base case. Despite discounted valuation, we believe other stocks in our coverage universe offer a better risk-reward on revenue and growth prospects. Bull/bear cases continue to hinge on Copaxone franchise durability. Brand pipeline success, cost cutting, and external deals could drive upside.”

Teva Pharmaceutical closed on Friday at $38.91.

Latest Ratings for TEVA

DateFirmActionFromTo
Oct 2014Standpoint ResearchUpgradesHoldBuy
Oct 2014Standpoint ResearchDowngradesBuyHold
Aug 2014UBSMaintainsNeutral

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters